國光生物科技股份有限公司
國光生物科技股份有限公司（Adimmune Corporation）從事疫苗及其他生物製品的開發、製造與分銷。提供「AdimFlu-S」四價流感疫苗及破傷風類毒素產品。此外研發新冠肺炎疫苗、H5N1 疫苗及細胞培養之日本腦炎疫苗。公司成立於 1965 年，總部位於台灣台中。
該股 RSI(6) 為 71.0，處於偏高區間，短線追高風險提升。股價站上5日、20日、60日均線，跌破120日均線。KD 指標中性（K=67.8）；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-10 | -53 | 0 | +7 | -46 |
| 08-07 | +1,706 | 0 | +12 | +1,718 |
| 08-06 | +100 | 0 | -20 | +80 |
| 08-05 | +434 | 0 | 0 | +434 |
| 08-04 | +188 | 0 | -36 | +152 |
| 08-03 | +102 | 0 | -17 | +85 |
| 07-31 | -365 | 0 | +4 | -361 |
| 07-30 | -226 | 0 | +5 | -221 |
| 07-29 | -416 | 0 | +7 | -409 |
| 07-28 | -449 | 0 | +1 | -448 |
| 07-27 | -192 | 0 | +7 | -185 |
| 07-24 | -276 | 0 | 0 | -276 |
| 07-23 | -1,096 | 0 | 0 | -1,096 |
| 07-22 | +141 | 0 | -24 | +117 |
| 07-21 | +77 | 0 | -9 | +68 |
| 07-20 | -1 | 0 | +18 | +17 |
| 07-17 | -734 | 0 | -6 | -740 |
| 07-16 | -102 | 0 | +6 | -96 |
| 07-15 | +540 | 0 | -3 | +537 |
| 07-14 | -771 | 0 | +13 | -758 |
| 07-13 | -1,196 | 0 | +12 | -1,184 |
| 07-09 | +30 | 0 | -2 | +28 |
| 07-08 | -33 | 0 | 0 | -33 |
| 07-07 | +241 | 0 | +1 | +242 |
| 07-06 | +331 | 0 | +1 | +333 |
| 07-03 | +1,230 | 0 | -10 | +1,219 |
| 07-02 | -76 | 0 | 0 | -77 |
| 07-01 | +322 | 0 | -15 | +307 |
| 06-30 | +567 | 0 | -2 | +565 |
| 06-29 | +840 | 0 | +2 | +842 |
| 06-26 | -861 | 0 | -4 | -865 |
| 06-25 | -703 | 0 | +1 | -702 |
| 06-24 | +373 | 0 | 0 | +373 |
| 06-22 | -370 | 0 | -8 | -378 |
| 06-18 | -389 | 0 | -2 | -391 |
| 06-17 | +14 | 0 | -4 | +10 |
| 06-16 | -209 | 0 | -5 | -214 |
| 06-15 | +49 | 0 | +7 | +56 |
| 06-12 | +302 | 0 | -1 | +301 |
| 06-10 | -56 | 0 | +4 | -52 |
| 06-09 | -83 | 0 | -10 | -94 |
| 06-08 | +378 | 0 | +12 | +390 |
| 06-04 | +367 | 0 | +3 | +370 |
| 06-03 | +128 | 0 | +2 | +130 |
| 06-02 | +151 | 0 | -8 | +143 |
| 06-01 | +273 | 0 | +7 | +280 |
| 05-29 | +519 | 0 | -7 | +512 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/06 | 3724 萬 | +449.7% | -62.8% |
| 2026/05 | 677 萬 | -70.2% | +51.9% |
| 2026/04 | 2274 萬 | -65.3% | +474.4% |
| 2026/03 | 6548 萬 | +1019.6% | +2102.7% |
| 2026/02 | 585 萬 | -46.7% | -19.7% |
| 2026/01 | 1098 萬 | -46.7% | -82.2% |
| 2025/12 | 2059 萬 | -84.3% | -53.8% |
| 2025/11 | 1.31 億 | -78.0% | +537.9% |
| 2025/10 | 5.94 億 | +264.9% | +23.8% |
| 2025/09 | 1.63 億 | +123.6% | -52.3% |
| 2025/08 | 7282 萬 | -69.6% | -60.9% |
| 2025/07 | 2.40 億 | - | -33.6% |